Literature DB >> 8755635

Clonal T cell responses in tumor infiltrating lymphocytes from both regressive and progressive regions of primary human malignant melanoma.

P thor Straten1, J C Becker, T Seremet, E B Bröcker, J Zeuthen.   

Abstract

The T cell receptor (TCR) BV variable (V) gene repertoire of tumor infiltrating lymphocytes (TIL) found in progressive and regressive regions of the same primary human melanomas were characterized by reverse transcription coupled polymerase chain reaction (RT-PCR). After surgery, the tumors were divided into different parts which were judged as regressive or progressive regions by visual inspection. Subsequently this diagnosis was confirmed by histology. From a total of four primary melanomas analyzed, 2 were drawn to be HLA-A2+. Only relatively few BV-gene families were expressed at significant levels in each of the samples. Comparison of the BV-expression in regressive versus progressive regions of the same tumor revealed major differences in all cases examined. Direct sequencing of RT-PCR products indicated that highly expressed BV-gene families were of clonal origin in both the regressive and progressive regions. Together, these data strongly suggest the occurrence of clonal T cell responses in both regressive and progressive areas of the same primary tumor. The differences in expression of certain BV-genes may correlate with the functional activity of certain populations of tumor-infiltrating T cells.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8755635      PMCID: PMC507428          DOI: 10.1172/JCI118790

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  26 in total

1.  Autoradiography using storage phosphor technology.

Authors:  R F Johnston; S C Pickett; D L Barker
Journal:  Electrophoresis       Date:  1990-05       Impact factor: 3.535

2.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction.

Authors:  P Chomczynski; N Sacchi
Journal:  Anal Biochem       Date:  1987-04       Impact factor: 3.365

3.  HLA Class I nucleotide sequences, 1992.

Authors:  J Zemmour; P Parham
Journal:  Immunobiology       Date:  1993-01       Impact factor: 3.144

4.  Regression in malignant melanoma. A histologic feature without independent prognostic significance.

Authors:  J W Kelly; R W Sagebiel; M S Blois
Journal:  Cancer       Date:  1985-11-01       Impact factor: 6.860

Review 5.  Relationship of causative factors in spontaneous regression of cancer to immunologic factors possibly effective in cancer.

Authors:  W H Cole
Journal:  J Surg Oncol       Date:  1976       Impact factor: 3.454

6.  Analysis of T-cell receptor alpha/beta variability in lymphocytes infiltrating a melanoma metastasis.

Authors:  L Ferradini; S Roman-Roman; J Azocar; M F Avril; S Viel; F Triebel; T Hercend
Journal:  Cancer Res       Date:  1992-09-01       Impact factor: 12.701

Review 7.  Analysis of TCR usage in human tumors: a new tool for assessing tumor-specific immune responses.

Authors:  M Sensi; G Parmiani
Journal:  Immunol Today       Date:  1995-12

8.  Usage of T-cell receptor V beta chain genes in fresh and cultured tumor-infiltrating lymphocytes from human melanoma.

Authors:  E Weidmann; E M Elder; M Trucco; M T Lotze; T L Whiteside
Journal:  Int J Cancer       Date:  1993-05-28       Impact factor: 7.396

9.  In a small multideterminant peptide, each determinant is recognized by a different V beta gene segment.

Authors:  N K Nanda; K K Arzoo; E E Sercarz
Journal:  J Exp Med       Date:  1992-07-01       Impact factor: 14.307

Review 10.  Tumour progression and the nature of cancer.

Authors:  W H Clark
Journal:  Br J Cancer       Date:  1991-10       Impact factor: 7.640

View more
  14 in total

Review 1.  T cell receptor usage in malignant diseases.

Authors:  E Halapi; M Jeddi-Tehrani; A Osterborg; H Mellstedt
Journal:  Springer Semin Immunopathol       Date:  1999

2.  Characterization of T cell repertoire in patients with graft-versus-leukemia after donor lymphocyte infusion.

Authors:  E J Claret; E P Alyea; E Orsini; C C Pickett; H Collins; Y Wang; D Neuberg; R J Soiffer; J Ritz
Journal:  J Clin Invest       Date:  1997-08-15       Impact factor: 14.808

3.  CD28-mediated costimulation impacts on the differentiation of DC vaccination-induced T cell responses.

Authors:  H Voigt; D Schrama; A O Eggert; C S Vetter; K Müller-Blech; H M Reichardt; M H Andersen; J C Becker; F Lühder
Journal:  Clin Exp Immunol       Date:  2006-01       Impact factor: 4.330

4.  Clonal expansion of T lymphocytes in human melanoma metastases after treatment with a hapten-modified autologous tumor vaccine.

Authors:  M Sensi; C Farina; C Maccalli; R Lupetti; G Nicolini; A Anichini; G Parmiani; D Berd
Journal:  J Clin Invest       Date:  1997-02-15       Impact factor: 14.808

Review 5.  T cell receptor repertoire usage in cancer as a surrogate marker for immune responses.

Authors:  David Schrama; Cathrin Ritter; Jürgen C Becker
Journal:  Semin Immunopathol       Date:  2017-01-10       Impact factor: 9.623

6.  Selective growth, in vitro and in vivo, of individual T cell clones from tumor-infiltrating lymphocytes obtained from patients with melanoma.

Authors:  Juhua Zhou; Mark E Dudley; Steven A Rosenberg; Paul F Robbins
Journal:  J Immunol       Date:  2004-12-15       Impact factor: 5.422

7.  Fas/Fas ligand interaction in human colorectal hepatic metastases: A mechanism of hepatocyte destruction to facilitate local tumor invasion.

Authors:  K F Yoong; S C Afford; S Randhawa; S G Hubscher; D H Adams
Journal:  Am J Pathol       Date:  1999-03       Impact factor: 4.307

8.  Melanoma antigen recognition by tumour-infiltrating T lymphocytes (TIL): effect of differential expression of melan-A/MART-1.

Authors:  T Ramirez-Montagut; D M Andrews; A Ihara; S Pervaiz; F Pandolfi; P J Van Den Elsen; R Waitkus; L A Boyle; M Hishii; J T Kurnick
Journal:  Clin Exp Immunol       Date:  2000-01       Impact factor: 4.330

Review 9.  Oligoclonal T cells in human cancer.

Authors:  E Halapi
Journal:  Med Oncol       Date:  1998-12       Impact factor: 3.064

10.  Activation of preexisting T cell clones by targeted interleukin 2 therapy.

Authors:  P T Straten; P Guldberg; T Seremet; R A Reisfeld; J Zeuthen; J C Becker
Journal:  Proc Natl Acad Sci U S A       Date:  1998-07-21       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.